Allison Kutner

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised the underwriters of Shoulder Innovations, a medical technology company exclusively focused on transforming the shoulder surgical care market, in connection with Shoulder Innovations’ $75 million initial public offering (IPO).

Cooley advised Blue Owl (NYSE: OWL), a leading asset manager redefining alternatives, on an up to $500 million term loan facility for Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis.

Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.

Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).